Loading…
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Purpose of review As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse. Recent findings While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional th...
Saved in:
| Published in: | Current oncology reports 2024-12, Vol.26 (12), p.1651-1663 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c312t-566c22e963545c7f3bac4ea9a032f1f4c56e7054a1efac5eca3faf7c730b1ec83 |
| container_end_page | 1663 |
| container_issue | 12 |
| container_start_page | 1651 |
| container_title | Current oncology reports |
| container_volume | 26 |
| creator | Kalsi, Simran Galenkamp, Amanda L. Singh, Rohit Khosla, Atulya Aman McGranaghan, Peter Cintolo-Gonzalez, Jessica |
| description | Purpose of review
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent findings
While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms.
Summary
In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies. |
| doi_str_mv | 10.1007/s11912-024-01611-9 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11646270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3133462540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-566c22e963545c7f3bac4ea9a032f1f4c56e7054a1efac5eca3faf7c730b1ec83</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwBzggS1zKIeDxVxouVbVaYKUiJLRwtWbdSeoqiYOdLOLf43RL-Thw8kjzzOt35i2K58BfA-fVmwRQgyi5UCUHA1DWD4pj0FKVRpj64VILWcqq5kfFk5RuOBecn_HHxZGsTa61OS76LXa-Dy0NxDq8pjhipHFPjp1uy6_r1SuGwxVb9xRbP7RsM0wRO0o-DNixTd_PQ5jyFI6eEmtCZB9pwjTh5F0uOxxCj2_ZBftMe0_fnxaPGuwSPbt7T4ov79bb1Yfy8tP7zerisnQSxFRqY5wQVBuplXZVI3foFGGNXIoGGuW0oYprhUANOk0OZYNN5SrJd0DuTJ4U5wfdcd71dOXo1rYdo-8x_rABvf27M_hr24a9BTDKiIpnhdM7hRi-zZQm2_vkqMsbUZiTlSBlJrVa0Jf_oDdhjvk-C6WU0gBysSQOlIshpUjNvRvgdonTHuK0OU57G6et89CLP_e4H_mVXwbkAUi5NbQUf__9H9mfSiisRw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3144451138</pqid></control><display><type>article</type><title>Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review</title><source>Springer Nature</source><creator>Kalsi, Simran ; Galenkamp, Amanda L. ; Singh, Rohit ; Khosla, Atulya Aman ; McGranaghan, Peter ; Cintolo-Gonzalez, Jessica</creator><creatorcontrib>Kalsi, Simran ; Galenkamp, Amanda L. ; Singh, Rohit ; Khosla, Atulya Aman ; McGranaghan, Peter ; Cintolo-Gonzalez, Jessica</creatorcontrib><description>Purpose of review
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent findings
While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms.
Summary
In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.</description><identifier>ISSN: 1523-3790</identifier><identifier>ISSN: 1534-6269</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-024-01611-9</identifier><identifier>PMID: 39602056</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvants ; Biological Products - therapeutic use ; Cytokines ; Drug dosages ; Herpes viruses ; Herpesvirus 1, Human ; Humans ; Hydrogels ; Illnesses ; Immunity (Disease) ; Immunomodulation ; Immunotherapy ; Immunotherapy - methods ; Injections, Intralesional ; Lymphatic system ; Lymphocytes ; Medicine ; Medicine & Public Health ; Melanoma ; Melanoma - immunology ; Melanoma - therapy ; Metastases ; Metastasis ; Oncology ; Oncolytic Virotherapy - methods ; Review ; Reviews ; Skin Neoplasms - immunology ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Topical Collection on Melanoma ; Toxicity</subject><ispartof>Current oncology reports, 2024-12, Vol.26 (12), p.1651-1663</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>Copyright Springer Nature B.V. Dec 2024</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c312t-566c22e963545c7f3bac4ea9a032f1f4c56e7054a1efac5eca3faf7c730b1ec83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39602056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalsi, Simran</creatorcontrib><creatorcontrib>Galenkamp, Amanda L.</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Khosla, Atulya Aman</creatorcontrib><creatorcontrib>McGranaghan, Peter</creatorcontrib><creatorcontrib>Cintolo-Gonzalez, Jessica</creatorcontrib><title>Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of review
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent findings
While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms.
Summary
In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.</description><subject>Adjuvants</subject><subject>Biological Products - therapeutic use</subject><subject>Cytokines</subject><subject>Drug dosages</subject><subject>Herpes viruses</subject><subject>Herpesvirus 1, Human</subject><subject>Humans</subject><subject>Hydrogels</subject><subject>Illnesses</subject><subject>Immunity (Disease)</subject><subject>Immunomodulation</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Injections, Intralesional</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Melanoma - immunology</subject><subject>Melanoma - therapy</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Review</subject><subject>Reviews</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Topical Collection on Melanoma</subject><subject>Toxicity</subject><issn>1523-3790</issn><issn>1534-6269</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoqXwBzggS1zKIeDxVxouVbVaYKUiJLRwtWbdSeoqiYOdLOLf43RL-Thw8kjzzOt35i2K58BfA-fVmwRQgyi5UCUHA1DWD4pj0FKVRpj64VILWcqq5kfFk5RuOBecn_HHxZGsTa61OS76LXa-Dy0NxDq8pjhipHFPjp1uy6_r1SuGwxVb9xRbP7RsM0wRO0o-DNixTd_PQ5jyFI6eEmtCZB9pwjTh5F0uOxxCj2_ZBftMe0_fnxaPGuwSPbt7T4ov79bb1Yfy8tP7zerisnQSxFRqY5wQVBuplXZVI3foFGGNXIoGGuW0oYprhUANOk0OZYNN5SrJd0DuTJ4U5wfdcd71dOXo1rYdo-8x_rABvf27M_hr24a9BTDKiIpnhdM7hRi-zZQm2_vkqMsbUZiTlSBlJrVa0Jf_oDdhjvk-C6WU0gBysSQOlIshpUjNvRvgdonTHuK0OU57G6et89CLP_e4H_mVXwbkAUi5NbQUf__9H9mfSiisRw</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Kalsi, Simran</creator><creator>Galenkamp, Amanda L.</creator><creator>Singh, Rohit</creator><creator>Khosla, Atulya Aman</creator><creator>McGranaghan, Peter</creator><creator>Cintolo-Gonzalez, Jessica</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241201</creationdate><title>Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review</title><author>Kalsi, Simran ; Galenkamp, Amanda L. ; Singh, Rohit ; Khosla, Atulya Aman ; McGranaghan, Peter ; Cintolo-Gonzalez, Jessica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-566c22e963545c7f3bac4ea9a032f1f4c56e7054a1efac5eca3faf7c730b1ec83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adjuvants</topic><topic>Biological Products - therapeutic use</topic><topic>Cytokines</topic><topic>Drug dosages</topic><topic>Herpes viruses</topic><topic>Herpesvirus 1, Human</topic><topic>Humans</topic><topic>Hydrogels</topic><topic>Illnesses</topic><topic>Immunity (Disease)</topic><topic>Immunomodulation</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Injections, Intralesional</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Melanoma - immunology</topic><topic>Melanoma - therapy</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Review</topic><topic>Reviews</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Topical Collection on Melanoma</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalsi, Simran</creatorcontrib><creatorcontrib>Galenkamp, Amanda L.</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Khosla, Atulya Aman</creatorcontrib><creatorcontrib>McGranaghan, Peter</creatorcontrib><creatorcontrib>Cintolo-Gonzalez, Jessica</creatorcontrib><collection>Springer_OA刊</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalsi, Simran</au><au>Galenkamp, Amanda L.</au><au>Singh, Rohit</au><au>Khosla, Atulya Aman</au><au>McGranaghan, Peter</au><au>Cintolo-Gonzalez, Jessica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>26</volume><issue>12</issue><spage>1651</spage><epage>1663</epage><pages>1651-1663</pages><issn>1523-3790</issn><issn>1534-6269</issn><eissn>1534-6269</eissn><abstract>Purpose of review
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent findings
While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms.
Summary
In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>39602056</pmid><doi>10.1007/s11912-024-01611-9</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2024-12, Vol.26 (12), p.1651-1663 |
| issn | 1523-3790 1534-6269 1534-6269 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11646270 |
| source | Springer Nature |
| subjects | Adjuvants Biological Products - therapeutic use Cytokines Drug dosages Herpes viruses Herpesvirus 1, Human Humans Hydrogels Illnesses Immunity (Disease) Immunomodulation Immunotherapy Immunotherapy - methods Injections, Intralesional Lymphatic system Lymphocytes Medicine Medicine & Public Health Melanoma Melanoma - immunology Melanoma - therapy Metastases Metastasis Oncology Oncolytic Virotherapy - methods Review Reviews Skin Neoplasms - immunology Skin Neoplasms - pathology Skin Neoplasms - therapy Topical Collection on Melanoma Toxicity |
| title | Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A34%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Talimogene%20laherparepvec%20(T-VEC)%20and%20Emerging%20Intralesional%20Immunotherapies%20for%20Metastatic%20Melanoma:%20A%20Review&rft.jtitle=Current%20oncology%20reports&rft.au=Kalsi,%20Simran&rft.date=2024-12-01&rft.volume=26&rft.issue=12&rft.spage=1651&rft.epage=1663&rft.pages=1651-1663&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-024-01611-9&rft_dat=%3Cproquest_pubme%3E3133462540%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c312t-566c22e963545c7f3bac4ea9a032f1f4c56e7054a1efac5eca3faf7c730b1ec83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3144451138&rft_id=info:pmid/39602056&rfr_iscdi=true |